Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • Thursday
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateBusiness Wire • 03/18/24
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's DiseaseBusiness Wire • 03/14/24
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark OfficeBusiness Wire • 01/29/24
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.Business Wire • 12/27/23
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1Business Wire • 12/18/23
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTIBusiness Wire • 11/28/23
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 MillionBusiness Wire • 10/23/23
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 09/21/23
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementBusiness Wire • 09/21/23
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.Business Wire • 08/02/23
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1Business Wire • 06/29/23
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's DiseaseBusiness Wire • 06/12/23
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private PlacementBusiness Wire • 06/05/23
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsBusiness Wire • 05/15/23
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)Business Wire • 05/02/23
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq RulesBusiness Wire • 04/21/23
Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial ResultsBusiness Wire • 03/20/23
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent AchievementsBusiness Wire • 01/11/23
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch EventBusiness Wire • 01/10/23
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's DiseaseBusiness Wire • 01/09/23